A large team of medical researchers at Memorial Sloan Kettering Cancer Center, in New York, working with colleagues from the Icahn School of Medicine at Mount Sinai and German firm BioNTech has developed a personalized mRNA vaccine that shows promise against an aggressive form of pancreatic cancer in clinical trial results.
Personalized mRNA vaccine to treat aggressive pancreatic cancer in clinical trial
